HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies
Cancer Discovery
LabNarrative concept · prepared as an independent design proposal
Publications
Recent and defining work
Selected research outputs that define the laboratory’s scientific direction and emerging programme.
↗
Whole-genome doubling drives immune evasion by silencing antigen presentation
Cancer Cell
Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies
Proceedings of the National Academy of Sciences
HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial
Journal of Clinical Investigation
Loss of Kmt2c or Kmt2d drives brain metastasis via KDM6A-dependent upregulation of MMP3
Nature Cell Biology
Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing HIF-1α levels
Proceedings of the National Academy of Sciences
The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
Cell Reports